跳至主要内容
临床试验/NCT03991455
NCT03991455已完成不适用

Evaluation of Safety and Efficacy of the Apyx™ Device for the Repair of Pelvic Organ Prolapse (POP)

Escala Medical LTD2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2019年10月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
17
试验地点
2
主要终点
Change in PFDI-20 Prolapse Subscale (POPDI-6) score

研究概览

简要总结

The aim of this study is to further evaluate this minimally invasive SSLF technique with respect to safety, clinical effectiveness, and patient satisfaction. The procedure will be performed in women electing to undergo surgical repair of their prolapse who wish to preserve their uterus, and will be evaluated using standardized measures and questionnaires.

详细描述

This study will evaluate sacrospinous ligament fixation using an incision-free technique - a technique that was developed with the goal of offering a technically simple, safe, and effective alternative to surgical prolapse repair procedures. When compared to previously reported SSLF methods, this technique has undergone novel modifications with the intent of maximizing efficacy and minimizing invasiveness. First, each sacrospinous ligament is approached trans-vaginally using a small diameter, low profile needle as the delivery platform for the anchoring unit. Secondly, the suspension is bilateral, thus maintaining vaginal length and width without deviation or narrowing of the vagina as might occur with a traditional (unilateral) sacrospinous repair. And third, using bio-degradable sutures and a securing element that stabilizes the fixation as opposed to performing an incision in the vaginal wall for suturing enables an incision-free procedure leaving the vagina free of any device after a period of several weeks.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women with prolapse electing to undergo reconstructive vaginal surgery for primary uterovaginal prolapse, who wish to enroll in this trial of an incision-free prolapse repair technique, after being familiarized with the suspected benefits and risks of the procedure.
  • Ages 18-90 years old
  • POP-Q Stage 2 or greater with an apical support defect, also defined as uterovaginal prolapse
  • Desire of uterine preservation
  • Patient is willing to return for follow-up evaluation and questionnaire completion at 3 months, 6 months, and 12 months, in addition to routine postoperative standard of care.
  • English fluency

排除标准

  • Previous vaginal, abdominal, or laparoscopic repair for pelvic organ prolapse
  • Prior hysterectomy
  • Known allergy to Nitinol / Stainless Steel / Polydioxanone.
  • Suspected uterine pathology, including malignancy.
  • History of chronic pelvic pain, interstitial cystitis or fibromyalgia.
  • Women diagnosed with symptomatic uterine fibroids, cervical elongation or hypertrophy, abnormal uterine or vaginal bleeding.
  • History of Pelvic Inflammatory Disease (PID)
  • Prior pelvic radiation therapy or malignancy.
  • Diagnosis of reproductive tract anomalies.
  • Pregnant or lactating women.
  • Participation in another trial
  • Inability to provide informed consent for study enrollment
  • PI's subjective assessment that study procedure will not plausibly correct patient pelvic organ prolapse symptoms due to anatomic considerations

结局指标

主要结局

Change in PFDI-20 Prolapse Subscale (POPDI-6) score

时间窗: 6 months

Pelvic Floor Disability Index (PFDI-20) includes 20 questions are rated from 0 to 4, with 0 is no present of distress and 4 is the highest of symptom scale. Pelvic Floor Disability Index distress index is a subscale of the first 6 questions of the above scale

次要结局

  • Objective success rate(6 months)
  • PGI-I(3 months, 6 months, and 12 months)
  • Unanticipated Device-related Serious Adverse Event rate(at intervals of 2 weeks, 3 months, 6 months, and 12 months)
  • Change in PFDI-20(at baseline 3 months, 6 months, and 12 months compared to preoperative)
  • Change in PISQ-12 scores(at baseline 3 months, 6 months, and 12 months compared to preoperative)

研究者

发起方
Escala Medical LTD
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验